Clinical Characteristics and Disease Course of Fibrosing Interstitial Lung Disease Patients in a Real-World Setting

被引:1
|
作者
Kilpelainen, Maritta [1 ,2 ]
Hirvonen, Tuuli [1 ,2 ]
Perkonoja, Katariina [3 ]
Hirsjarvi, Samuli [4 ]
机构
[1] Turku Univ Hosp, Dept Pulm Dis, Turku 20500, Finland
[2] Univ Turku, Turku 20500, Finland
[3] Turku Univ Hosp, Hosp Dist Southwest Finland, Auria Clin Informat, Turku 20521, Finland
[4] Boehringer Ingelheim Finland Ky, Helsinki 00180, Finland
来源
MEDICINA-LITHUANIA | 2023年 / 59卷 / 02期
关键词
real-world data; interstitial lung disease; idiopathic pulmonary fibrosis; progressive pulmonary fibrosis; incidence; prevalence; IDIOPATHIC PULMONARY-FIBROSIS;
D O I
10.3390/medicina59020281
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives: This single-center retrospective study was conducted to describe clinical characteristics and the disease course of patients with interstitial lung diseases (ILD). Materials and Methods: The study included adult patients with fibrosing ILD (IPF, non-IPF fibrosing ILD (F-ILD), and non-IPF progressive pulmonary fibrosis (PPF)) treated between 2014 and 2017. Patients were followed annually from the first visit until the end of the study period in 2019. Data were collected from the Turku University Hospital data lake and analyzed using descriptive statistics. Results: 591 patients formed the patient cohort: 110 had IPF, 194 F-ILD, 142 PPF, and the remaining 145 patients were uncertain, F-ILD-U, whose disease progression nature could not be confirmed by FVC measurements. There were more males in each patient group and median age of the groups was similar, although there were younger patients in the PPF, F-ILD, and F-ILD-U groups. PPF patients had more UIP pattern than F-ILD patients. Exposure-related ILDs were clearly the most found ILD diagnoses for both PPF and F-ILD, followed by unclassifiable IIP. Baseline FVC % predicted reduction in every group was moderate. Half of the patients in each group had comorbidities, and the most common were cardiovascular diseases, diabetes, sleep apnea, and chronic lower respiratory diseases; F-ILD-U patients had malignant diseases as well. IPF patients had less medications than the other groups. Glucocorticoids were the most used medication in all patient groups. More PPF and F-ILD patients remained in the follow-up than IPF and F-ILD-U patients. Similarly, mortality of F-ILD-U was the highest, followed by IPF. Evolvement of lung function, oxygen use, and number of acute hospitalizations were similar for IPF and PPF patients whereas the corresponding results were always better for F-ILD patients. Conclusions: The disease course of IPF and PPF was similar, and PPF patient amount exceeded the amount of IPF patients.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Progression of fibrosing interstitial lung disease
    Wong, Alyson W.
    Ryerson, Christopher J.
    Guler, Sabina A.
    RESPIRATORY RESEARCH, 2020, 21 (01)
  • [22] Prognostic Predictive Characteristics in Patients With Fibrosing Interstitial Lung Disease: A Retrospective Cohort Study
    Wang, Yuanying
    Guo, Ziyun
    Ma, Ruimin
    Wang, Jingwei
    Wu, Na
    Fan, Yali
    Ye, Qiao
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [23] Pirfenidone in Patients with Unclassifiable Progressive Fibrosing Interstitial Lung Disease: Demographic and Baseline Characteristics
    Maher, T. M.
    Corte, T. J.
    Fischer, A.
    Kreuter, M.
    Lederer, D. J.
    Molina-Molina, M.
    Samara, K.
    Axmann, J.
    Kirchgaessler, K.
    Cottin, V.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [24] Lung Function Decline and Hospitalization Among Patients with non-IPF Fibrosing Interstitial Lung Disease as Observed in a Large Real-World Electronic Health Record Database
    Singer, D.
    Chastek, B. J.
    Johnson, J. C.
    Shetty, S.
    Conoscenti, C. S.
    Bernstein, E. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [25] Closing the Evidence Gap in Interstitial Lung Disease The Promise of Real-World Data
    Farrand, Erica
    Anstrom, Kevin J.
    Bernard, Gordon
    Butte, Atul J.
    Iribarren, Carlos
    Ley, Brett
    Martinez, Fernando J.
    Collard, Harold R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199 (09) : 1061 - 1065
  • [26] Interstitial Lung Disease and Pulmonary Hypertension in Systemic Sclerosis: A Real-World Experience
    Sangani, R.
    Schoenberg, N.
    Chen, C.
    Dukes, K.
    Klings, E. S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [27] CHARACTERISTICS AND DISEASE COURSE OF UNTREATED PATIENTS WITH INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS
    Scheidegger, M.
    Garaiman, A.
    Mihai, C.
    Becker, M. O.
    Dobrota, R.
    Bruni, C.
    Jordan, S.
    Fretheim, H.
    Midtvedt, O.
    Bjorkekjaer, H. J.
    Barua, I.
    Hoffmann-Vold, A. M.
    Distler, O.
    Elhai, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 735 - 736
  • [28] Supportive care of patients with fibrosing interstitial lung disease: answering a great clinical need
    Goodwin, Amanda T.
    Saini, Gauri
    BREATHE, 2020, 16 (03) : 1 - 4
  • [29] Comprehensive Supportive Care for Patients with Fibrosing Interstitial Lung Disease
    Wijsenbeek, Marlies S.
    Holland, Anne E.
    Swigris, Jeffrey J.
    Renzoni, Elisabetta A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 200 (02) : 152 - 159
  • [30] Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting
    Assie, Jean-Baptiste
    Chouaid, Christos
    Nunes, Hilario
    Reynaud, Dorothee
    Gaudin, Anne-Francoise
    Grumberg, Valentine
    Jolivel, Ronan
    Jouaneton, Baptiste
    Cotte, Francois-Emery
    Duchemann, Boris
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15